作者
VC Tam, YJ Ko, N Mittmann, MC Cheung, K Kumar, S Hassan, KKW Chan
发表日期
2013/4
期刊
Current oncology
卷号
20
期号
2
页码范围
e90
出版商
Multidisciplinary Digital Publishing Institute (MDPI)
简介
Purpose
Gemcitabine and capecitabine (gem-cap), gemcitabine and erlotinib (gem-e), and folfirinox (5-fluorouracil–leucovorin–irinotecan–oxaliplatin) are new treatment options for metastatic pancreatic cancer, but they are also more expensive and potentially more toxic than gemcitabine alone (gem). We conducted a cost-effectiveness analysis of these treatment options compared with gem.
Methods
A Markov model was constructed to examine costs and outcomes of gem-cap, gem-e, folfirinox, and gem in patients with metastatic pancreatic cancer from the perspective of a government health care plan. Ontario health economic and costing data (2010 Canadian dollars) were used. Efficacy data for the treatments were obtained from the published literature. Resource utilization data were derived from a chart review of consecutive metastatic patients treated for pancreatic cancer at Princess Margaret Hospital, Toronto …
学术搜索中的文章
VC Tam, YJ Ko, N Mittmann, MC Cheung, K Kumar… - Current oncology, 2013